Advertisement

U.S. markets open in 8 hours 45 minutes

S&P Futures
3,853.00
+4.75(+0.12%)
Dow Futures
31,053.00
+40.00(+0.13%)
Nasdaq Futures
11,905.75
+25.50(+0.21%)
Russell 2000 Futures
1,732.70
+4.10(+0.24%)
Crude Oil
98.97
+0.44(+0.45%)
Gold
1,743.20
+6.70(+0.39%)

Advertisement

Chinook Therapeutics, Inc. (KDNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

18.65

+0.34

(+1.86%)

At close: 04:00PM EDT

18.65

0.00

(0.00%)

After hours:

04:02PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	18.31
Open	18.37
Bid	18.64 x 3000
Ask	19.85 x 800
Day's Range	18.17 - 18.76
52 Week Range	10.48 - 19.59
Volume	960,799
Avg. Volume	665,606

Market Cap	1.149B
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.96
Earnings Date	Aug 01, 2022 - Aug 05, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	34.63

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KDNY

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Chinook Therapeutics, Inc.
Technical Assessment: Bearish in the Intermediate-TermCommodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.
Rating
Fair Value
Economic Moat
22 hours agoArgus Research

All

GlobeNewswire
Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a fireside chat and 1x1 meetings at the William Blair Biotech Focus Conference 2022. The fireside chat will be available on-demand beginning Monday, July 11th at 9:00 am EDT and Chinook management will participa
- Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
  Business Wire
- Cullinan Oncology to Participate in William Blair Biotech Focus Conference
  GlobeNewswire
GlobeNewswire
Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). Orp
Simply Wall St.
Could The Chinook Therapeutics, Inc. (NASDAQ:KDNY) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Chinook Therapeutics, Inc. ( NASDAQ:KDNY ) can tell us which group is most powerful...